Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia

被引：5
|
作者：
Patel, Shyam A. [1 ,2 ]
机构：
[1] Stanford Univ, Dept Med, Div Hematol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Div Oncol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
来源：
JAMA ONCOLOGY | 2018年 / 4卷 / 08期
关键词：
MUTATIONS;
D O I：
10.1001/jamaoncol.2017.4724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1110 / +
页数：3
相关论文
共 50 条
  • [41] Epigenetic deregulation of β-catenin pathway inhibitors in the bone marrow stroma promotes development of IDH1-and IDH2-mutant myelodysplastic syndromes and acute myeloid leukemia and correlates with resistance to treatment
    Vgenopoulou, Paraskevi
    Zhao, Junfei
    Delestre, Laure
    Penard-Lacronique, Virginie
    Liu, Shawn
    Carroll, Martin
    Kousteni, Stavroula
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 2 - 2
  • [42] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
    Atluri, Himachandana
    Maiti, Abhishek
    Sasaki, Koji
    Daver, Naval
    Alvarado, Yesid
    Hossain, Md Feroz
    Wang, Xuemei
    Pemmaraju, Naveen
    Takahashi, Koichi
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Short, Nicholas
    Abbas, Hussein A.
    Ravandi, Farhad
    Jabbour, Elias
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Konopleva, Marina
    DiNardo, Courtney D.
    BLOOD, 2022, 140 : 6170 - 6172
  • [43] Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
    Birendra, K. C.
    DiNardo, Courtney D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (08): : 460 - 465
  • [44] Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Berton, Guillaume
    Schaefer, Eva J.
    Zeidan, Amer M.
    Goldberg, Aaron
    Stein, Eytan
    Marcucci, Guido
    Bystrom, Rebecca P.
    Lindsley, R. Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony
    Pullarkat, Vinod
    Aldoss, Ibrahim
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Garciaz, Sylvain
    Ball, Brian
    Stahl, Maximilian
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1640 - 1643
  • [45] Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy
    Kallen, Michael E.
    Koka, Rima
    Singh, Zeba
    Sanchez-Petitto, Gabriela
    Zaman, Qamar U.
    Yared, Jean A.
    Duong, Vu H.
    LEUKEMIA RESEARCH, 2020, 96
  • [46] Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
    Zeng, Zhihong
    Konopleva, Marina
    HAEMATOLOGICA, 2021, 106 (02) : 324 - 326
  • [47] Vorasidenib in IDH1-or IDH2-Mutant Low-Grade Glioma
    Mellinghoff, Ingo K.
    van den Bent, Martin J.
    Blumenthal, Deborah T.
    Touat, Mehdi
    Peters, Katherine B.
    Clarke, Jennifer
    Mendez, Joe
    Yust-Katz, Shlomit
    Welsh, Liam
    Mason, Warren P.
    Ducray, Francois
    Umemura, Yoshie
    Nabors, Burt
    Holdhoff, Matthias
    Hottinger, Andreas F.
    Arakawa, Yoshiki
    Sepulveda, Juan M.
    Wick, Wolfgang
    Soffietti, Riccardo
    Perry, James R.
    Giglio, Pierre
    de la Fuente, Macarena
    Maher, Elizabeth A.
    Schoenfeld, Steven
    Zhao, Dan
    Pandya, Shuchi S.
    Steelman, Lori
    Hassan, Islam
    Wen, Patrick Y.
    Cloughesy, Timothy F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (07): : 589 - 601
  • [48] Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
    Venugopal, Sangeetha
    Takahashi, Koichi
    Daver, Naval
    Maiti, Abhishek
    Borthakur, Gautam
    Loghavi, Sanam
    Short, Nicholas J.
    Ohanian, Maro
    Masarova, Lucia
    Issa, Ghayas
    Wang, Xuemei
    Carlos, Bueso-Ramos
    Yilmaz, Musa
    Kadia, Tapan
    Andreeff, Michael
    Ravandi, Farhad
    Konopleva, Marina
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    BLOOD CANCER JOURNAL, 2022, 12 (01)
  • [49] Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma
    Moore, Donald C.
    Nelson, Viera
    Muslimani, Alaa
    ANNALS OF HEMATOLOGY, 2021, 100 (12) : 3053 - 3055
  • [50] Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma
    Donald C. Moore
    Viera Nelson
    Alaa Muslimani
    Annals of Hematology, 2021, 100 : 3053 - 3055
12345